Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations (ILIADE)

Impact of a Strategy Dedicated to Low Health Literacy Level Patients to Improve Their Understanding and Ownership of the Discharge Prescription in Cardio-vascular Diseases

Health literacy is the ability to access, understand, evaluate and apply information in order to communicate with health professionals and understand health instructions but also, promote, maintain and improve health throughout life. Health literacy is known as a health determinant. Level of Health Literacy is low or limited within 47% of interrogated people in Europe, resulting in an inability to understand and/or use written texts and digital concepts about one's health.

There is a demonstrated link between low HL and low therapeutic adherence, an increase in the number of re-admissions, and more generally poor health or survival that is even more limited. An association between low LS and higher health care costs has also been reported in the USA and Switzerland. WHO highlight the central role of Health Literacyin health inequalities, regardless of the region of the world.

The investigator chose to conduct this study in patients hospitalized for an acute cardiovascular event: acute myocardial infarction or acute decompensated heart failure , as these patients have cumulative risk factors for misuse and medication errors. They are hospitalized in emergency, for shorter and shorter periods and are discharged with complex drug treatments. The data show that the return home after acute hospitalization for these conditions is a particularly high-risk period for medication errors and misuse, especially with low level of Health Literacy. The proportion of patients with preventable adverse events in the weeks following their return home ranges from 23% to 30% and nearly 60% are re-hospitalized within 6 months.

The hypothesis of the study is that in patients hospitalized for cute myocardial infarctionor acute decompensated heart failurewith low Health Literacy levels, information on discharge treatment using appropriate tools and techniques will reduce the risk of patient-related medication errors or misuse within 30 days of discharge.

The purpose of this study is to develop an educational intervention model adapted to low Health Literacy levels and routinely feasible, even in case of short stays, in complementarity with traditional therapeutic education programmes that require higher investments and are therefore not accessible to all patients. This innovative approach could then be applied to a large number of chronic diseases.

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Decompensated Heart Failure; Acute Myocardial Infarction
• Intervention / Treatment: Other: Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.

• Study Type: Interventional
• Enrollment (Estimated): 300
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Julie HAESEBAERT, MD; Phone Number: +33 04 72 68 49 05; Email: julie.haesebaert@chu-lyon.fr
• Study Contact Backup: Name: Estelle BRAVANT; Phone Number: +33 04 27 85 63 18; Email: estelle.bravant@chu-lyon.fr

Study Locations

• France
  • Lyon, France
    • Public Health Department
    • Contact: Julie HAESEBAERT, MD; Phone Number: +33 04 72 68 49 05; Email: julie.haesebaert@chu-lyon.fr
    • Contact: Estelle BRAVANT; Phone Number: +33 04 27 85 63 18; Email: estelle.bravant@chu-lyon.fr
    • Principal Investigator: Julie HAESEBAERT, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age greater than or equal to 18 years
• Hospitalization for at least a 2nd acute attack (systolic or diastolic)
• Patient living at home before hospitalization for decompensation
• Affiliated with a health insurance plan

Exclusion Criteria:

• Short-term vital prognosis
• Bipolar disorders, active psychoses
• Severe dementia
• Psychiatric or cognitive comorbidities making inclusion impossible, at the discretion of the investigator.
• Pregnant, parturient or breastfeeding women
• Persons deprived of liberty by a judicial or administrative decision
• Persons admitted to a health or social establishment for purposes other than research
• Adults subject to a legal protection measure (guardianship, curatorship)
• Subject participating in another interventional research including an exclusion period still ongoing at inclusion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Interventional arm	Other: Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.; Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge. First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter. Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations. Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire.
No Intervention: Controlled arm; Patients within this arm will be follow as usual care of the cardiologic unit

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient-related medication errors or misuse within 30 days of discharge from hospital.	This criterion is defined as the proportion of patients who have made a medication error or misuse, with or without a clinical consequence. We will focus on patient-related medication errors and misuse, i.e. non-compliance with prescription (shorter or longer treatment time, dosage changes, self-medication, etc.), based on the definition proposed by Kripalani et al. An adjudication committee composed of three independent experts will be responsible for defining the potential severity of drug errors or misuses related to the main judgement criterion. Data on primary endpoint will be collected by a clinical researcher, blinded to the randomization group, using a standardized questionnaire administered during the 30-day telephone interview. The patient will be asked the names of the treatments, how he/she took them (number of units per intake, frequency of intake,...), self-medication taken and medical follow-up (medical consultations, biological follow-up,...) over the past 30 days.	Day 30

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon
• Investigators: Principal Investigator: Julie HAESEBAERT, MD, Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2024
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: May 14, 2019
• First Submitted That Met QC Criteria: May 14, 2019
• First Posted (Actual): May 15, 2019

Study Record Updates

• Last Update Posted (Estimated): December 11, 2023
• Last Update Submitted That Met QC Criteria: December 4, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Health promotion; Cardiovascular Diseases; Randomized Controlled Trial; Interventional study; Literacy; Tertiary prevention
• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Myocardial Infarction; Infarction
• Other Study ID Numbers: 69HCL19_0035

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No